The KRAS Mutation: Cancer Patients Search for Hard-To-Find Trials

The KRAS Mutation: Cancer Patients Search for Hard-To-Find Trials By Kathleen Hoffman, PhD, MSPH There is new hope for cancer patients with the mutated protein KRAS G12C, an oncogene previously thought to be “undruggable.”1 KRAS is one part of the RAS-RAF cellular signaling pathway that drives a cell to multiply, and its mutations are commonly present in pancreatic, colorectal, and non-small cell lung cancers (NSCLC), all of which have a poor prognosis.2 In 2013, the NIH National Cancer Institute founded the RAS Initiative for exploring approaches for attacking the proteins encoded by mutant forms of RAS genes, [...]